行情

CARA

CARA

Cara
NASDAQ

实时行情|Nasdaq Last Sale

17.31
+0.42
+2.46%
盘后: 17.31 0 0.00% 17:45 01/17 EST
开盘
17.05
昨收
16.89
最高
17.36
最低
16.93
成交量
68.50万
成交额
--
52周最高
27.55
52周最低
14.10
市值
8.08亿
市盈率(TTM)
-7.2324
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CARA 新闻

  • 小米大涨5%誓要重返17港元招股价 5大因素促使大涨
  • 新浪港股.21分钟前
  • 荔枝上市了,但音频还是好故事吗?
  • 新浪财经综合.28分钟前
  • 特斯拉在美遭投诉 50万辆车涉及“意外加速”风险
  • 界面.58分钟前
  • 华盛早报 | 特朗普弹劾案审讯在即,苹果完成新iPhone研发
  • 华盛通.1小时前

更多

所属板块

生物技术和医学研究
-0.16%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

CARA 简况

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body's peripheral nervous system. The Company operates through the activities related to the discovery and development of therapeutics to treat serious medical conditions, including pain and pruritus. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain. I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. CR845 has exhibited anti-pruritic, or anti-itch, potency in standard preclinical models.
展开

Webull提供Cara Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。